Oral fluoroquinolone use and risk of peripheral neuropathy

@article{Etminan2014OralFU,
  title={Oral fluoroquinolone use and risk of peripheral neuropathy},
  author={M. Etminan and J. Brophy and A. Samii},
  journal={Neurology},
  year={2014},
  volume={83},
  pages={1261 - 1263}
}
Objective: To quantify the risk of peripheral neuropathy (PN) with oral fluoroquinolone (FQ) use. Methods: We conducted a case-control study within a cohort of men aged 45 to 80 years in the United States followed from 2001 to 2011. Cases were defined as those with the first physician visit diagnosis of PN, polyneuropathy, or drug-induced polyneuropathy. Four controls were matched to each case by age, follow-up, and calendar time using density-based sampling. As a sensitivity analysis, we also… Expand
Association Between Peripheral Neuropathy and Exposure to Oral Fluoroquinolone or Amoxicillin-Clavulanate Therapy.
TLDR
Oral fluoroquinolone therapy was associated with an increased risk of incident peripheral neuropathy that may depend on the timing of the exposure and the cumulative dose, and health care professionals should consider these potential risks when prescribing fluoroquolone antibiotics. Expand
Oral Fluoroquinolone Prescribing to Children in the United States From 2006 to 2015
TLDR
Clinicians are advised to refrain from using FQs for uncomplicated community-acquired infections, and at least 1 in 5 prescriptions were deemed unnecessary over a 10-year period. Expand
Fluoroquinolone use for uncomplicated urinary tract infections in women: A retrospective cohort study.
  • N. Daneman, D. Chateau, +7 authors S. Bugden
  • Medicine
  • Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • 2019
TLDR
Fluentquinolones are associated with improved clinical outcomes among women with uncomplicated UTIs and must be weighed against risk of fluoroquinolone resistance and rare but serious fluoroquetolone side effects when selecting first line treatment for these patients. Expand
Do Fluoroquinolones Cause Neuropathy
TLDR
FDA recommends that patients with symptoms of peripheral neuropathy after taking systemic fluoroquinolone to stop the medication and to be treated with an alternative non-fluoroquolone antibacterial drug. Expand
Adverse Effects of Fluoroquinolones: A Retrospective Cohort Study in a South Indian Tertiary Healthcare Facility
TLDR
A harmful association between FQ use and the development of ADRs is concluded, and FQs are not safe compared to other antibiotics, Hence, the use of F Qs should be limited to the conditions where no other alternatives are available. Expand
Oral fluoroquinolones and risk of fibromyalgia
The Food and Drug Administration (FDA) has recently included a black box warning on fibromyalgia-like symptoms with fluoroquinolones (FQs) but no large epidemiologic study is to date available. WeExpand
Oral Fluoroquinolones and Risk of Mitral and Aortic Regurgitation.
TLDR
The results show that the risk of aortic and mitral regurgitation is highest with current use followed by recent use of fluoroquinolones, and no risk was observed with past use of FQs. Expand
Intractable Acute Pain Related to Fluoroquinolone-Induced Peripheral Neuropathy
TLDR
The patient is a 20-year-old male, with well-controlled type 1 diabetes mellitus, presenting with a short duration of bilateral lower extremity pain following a 10-day course of levofloxacin for suspected epididymitis. Expand
Tumor necrosis factor inhibitors and risk of peripheral neuropathy in patients with rheumatic diseases.
TLDR
Patients with rheumatic diseases who are past users of TNFi are at higher risk of developing PN compared to those taking methotrexate and one additional disease modifying anti-rheumatic drug (DMARD) for recent and past use. Expand
Addendum to: Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case–Control Study
TLDR
The results show the frequency of tendon rupture events varies across the population depending on several factors: namely duration of therapy, age, gender and concomitant exposure to systemic corticosteroids. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 13 REFERENCES
Peripheral Neuropathy Associated with Fluoroquinolones
TLDR
These cases suggest a possible association between fluoroquinolone antibiotics and severe, long-term adverse effects involving the PNS as well as other organ systems, and should prompt immediate discontinuation of the agent used. Expand
Peripheral neuropathy and Guillain-Barré syndrome risks associated with exposure to systemic fluoroquinolones: a pharmacovigilance analysis.
  • A. Ali
  • Medicine
  • Annals of epidemiology
  • 2014
TLDR
This study re-emphasizes the link between fluoroquinolones and PN and shows the potential association with more severe forms of nerve damage, for example, GBS. Expand
Fluoroquinolone toxicity profiles: a review focusing on newer agents.
  • Benjamin A Lipsky, C. Baker
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1999
TLDR
Fluoroquinolones are safe in elderly, human immunodeficiency virus-infected, and neutropenic patients, but because of possible effects on articular cartilage, they are not currently recommended for children or pregnant women. Expand
Toxicity of Quinolones
TLDR
Overall, quinolones are well tolerated drugs, but their specific toxic potentials have to be considered when they are chosen for treatment of bacterial infections. Expand
Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology
TLDR
A temporal association between tamsulosin use for benign prostatic hyperplasia and severe hypotension during the firstEight weeks after initiating treatment and the first eight weeks after restarting treatment is observed, suggesting that physicians should focus on improving counseling strategies to warn patients regarding the “first dose phenomenon” with tamsULosin. Expand
Neurotoxicity of antibacterial therapy.
The increasing variety of drugs available for the treatment of bacterial infections has simultaneously increased the potential for toxicity. Neurologic toxicity of antibacterial therapy is generallyExpand
Fluoroquinolone prescribing in the United States: 1995 to 2002.
TLDR
Fluoroquinolone prescribing increased threefold in outpatient clinics and emergency departments in the United States from 1995 to 2002, and became the most commonly prescribed class of antibiotics to adults in 2002. Expand
The nested case-control study in cardiology.
TLDR
The large cohorts of cardiac patients created by prospective studies, clinical trials, and administrative databases should be exploited using this methodology to assess potential cardiac risk factors and other causal relationships that cannot be studied in randomized trials. Expand
From the Food and Drug Administration.
After an initial reading and a rereading of the FDA’s white paper, “Innovation Stagnation Challenge and Opportunity on the Critical Path to New Medical Products” and a thoughtful reading of theExpand
Drug safety communication Available at: http://www.fda.gov/downloads/Drugs/ DrugSafety/UCM365078.pdf
  • Drug safety communication Available at: http://www.fda.gov/downloads/Drugs/ DrugSafety/UCM365078.pdf
  • 2014
...
1
2
...